PP49 Financing The Line Of Care In The First Biochemical Relapse Of Prostate Cancer After [⁶⁸Ga] PSMA PET- CT

Introduction It is estimated that prostate cancer will reach 66 thousand by the triennium 2020-2022 according to National Cancer Institute (INCA). After initial diagnosis and staging patient may undergo radical prostatectomy and/or curative radiotherapy. In patients with biochemical relapse (PSA >0.2 ng/ml) initially treated prostatectomy, salvage external radiotherapy indicated. The [ 68 Ga] Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography (PSMA PET-CT) scan mainly used for localization of in setting first recurrence can significantly influence clinical management patient. Methods overall objective this work perform a treatment cost analysis after performing PSMA PET-CT from perspective Brazilian Health System (SUS). A decision tree was constructed through consultation experts outline patient’s entire treatment. Values per modelled therapeutic procedure were surveyed two different scenarios, without PET-CT. average scenario 1 stereotaxic radiation therapy (SBRT), rescue androgen deprivation (ADT). 2, it ADT. reimbursement table prepared data collected SUS system. Variations analyzed using sensitivity study. Total values included: individual procedure, medical (up 3 years) population percentage Results calculated currency (BRL) each procedure. total amount BRL 264,965,465.00 (USD 55,642,747.65) 2 123,585,612.72 26,162,978.67). Conclusions line care adopted an important information expand access population. shows increased adoption. prospective study should be considered high follow up.